Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karan Sra

Dermatology Webster, TX Medical Doctor

NPI 1043414634 CMS profile 229325

202 N Texas Ave Ste 300, Webster, TX 77598

Open in the dashboard

General payments

$104,889

575 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karan Sra of Webster, TX is reported in the CMS Open Payments database as having received $104,889 across 575 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $537 18
2024 General $3,097 36
2023 General $7,122 40
2022 General $16,818 47
2021 General $9,834 88
2020 General $14,401 95
2019 General $53,080 251

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karan Sra
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Karan Sra were reported at $537. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Karan Sra Dermatology median Middle half National median
2019 $53,080 $454 $129–$1,240 $163
2020 $14,401 $235 $81–$756 $114
2021 $9,834 $377 $108–$1,108 $132
2022 $16,818 $514 $143–$1,391 $149
2023 $7,122 $607 $159–$1,674 $160
2024 $3,097 $751 $204–$1,903 $164
2025 $537 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $68,635 167 payments
  2. Pfizer Inc. $27,296 45 payments
  3. Genzyme Corporation $1,777 19 payments
  4. Novartis Pharmaceuticals Corporation $907 37 payments
  5. Merz North America, Inc. $750 4 payments
  6. Janssen Biotech, Inc. $639 34 payments
  7. Revance Therapeutics, Inc. $555 11 payments
  8. Sun Pharmaceutical Industries Inc. $505 25 payments
  9. Amgen Inc. $456 29 payments
  10. LEO Pharma Inc. $400 23 payments
  11. Other $2,969 181 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89,198 41 payments
  2. Food and Beverage $11,799 506 payments
  3. Consulting Fee $1,978 2 payments
  4. Travel and Lodging $1,771 19 payments
  5. Education $143 7 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $55,322 114 payments
  2. EUCRISA $22,746 44 payments
  3. HUMIRA $9,313 41 payments
  4. CIBINQO $4,583 4 payments
  5. RINVOQ $3,581 22 payments
  6. DUPIXENT $1,739 15 payments
  7. COSENTYX $565 24 payments
  8. DAXXIFY $555 11 payments
  9. TREMFYA $479 24 payments
  10. STELARA $465 29 payments
  11. Other $5,553 332 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

966

Median for Dermatology: 534

Drug cost

$259,852

Median for Dermatology: $67,151

Branded share of claims

10.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 22 $105,800
Cosentyx Sensoready (2 Pens) Secukinumab Brand 12 $93,033
Dupixent Pen Dupilumab Brand 11 $41,095
Clobetasol Propionate Generic 119 $5,443
Metronidazole Generic 51 $2,348
Triamcinolone Acetonide Generic 286 $2,149
Fluorouracil Generic 28 $1,836
Doxycycline Hyclate Generic 70 $1,193
Ketoconazole Generic 80 $1,013
Betamethasone Dipropionate Generic 12 $936

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$457,440

Of which drugs: $20

Medicare patients

1,349

Average age 74

Services billed

11,036

779 women, 570 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 46%
Ischemic heart disease 30%
Diabetes 23%
Chronic kidney disease 18%
Depression 18%
Osteoporosis 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 26 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $1,345
$1,345 — —
SKYRIZI
  • AbbVie, Inc. $1,225
$1,225 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $267
$267 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $93
$93 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

575 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record